Levosimendan
Code | Size | Price |
---|
TAR-T2530-25mg | 25mg | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2530-50mg | 50mg | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2530-100mg | 100mg | £119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2530-200mg | 200mg | £153.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2530-500mg | 500mg | £261.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Levosimendan is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner.
CAS:
141505-33-1
Formula:
C14H12N6O
Molecular Weight:
280.291
Pathway:
Membrane transporter/Ion channel; Autophagy; Metabolism
Purity:
0.9991
SMILES:
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1
Target:
Potassium Channel; PDE; Carbonic Anhydrase; Autophagy
References
1. Haikala H, J Mol Cell Cardiol, 1995, 27(9), 1859-1866.
2. Yokoshiki H, Eur J Pharmacol, 1997, 333(2-3), 249-259.
3. Hasenfuss G, Circulation, 1998, 98(20), 2141-2147.
4. Slawsky MT, Circulation, 2000, 102(18), 2222-2227.
5. Edes I, Circ Res, 1995, 77(1), 107-113.